14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression

Li Qin, Zizheng Dong, Jian Ting Zhang

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Gemcitabine is an important anticancer therapeutics approved for treatment of several human cancers including locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Its clinical effectiveness, however, is hindered by existence of intrinsic and development of acquired resistances. Previously, it was found that 14-3-3σ expression associates with poor clinical outcome of PDAC patients. It was also found that 14-3-3σ expression is up-regulated in gemcitabine resistant PDAC cells and contributes to the acquired gemcitabine resistance. In this study, we investigated the molecular mechanism of 14-3-3σ function in gemcitabine resistance and found that 14-3-3σ up-regulates YAP1 expression and then binds to YAP1 to inhibit gemcitabine-induced caspase 8 activation and apoptosis. 14-3-3σ association with YAP1 up-regulates the expression of ribonucleotide reductase M1 and M2, which may mediate 14-3-3σ/YAP1 function in the acquired gemcitabine resistance. These findings suggest a possible role of YAP1 signaling in gemcitabine resistance.

Original languageEnglish (US)
Pages (from-to)17726-17736
Number of pages11
JournalOncotarget
Volume7
Issue number14
DOIs
StatePublished - Jan 1 2016

Keywords

  • 14-3-3σ
  • Gemcitabine resistance
  • Gene expression
  • Ribonucleotide reductase
  • YAP1

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of '14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression'. Together they form a unique fingerprint.

  • Cite this